André Vuilliomenet
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuilliomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PloS one 2019; 14:e0210821.
15.01.2019Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
15.01.2019PloS one 2019; 14:e0210821
Jeger Raban V, Weilenmann Daniel, Rickli Hans, Hansen Kim Wadt, Rickenbacher Peter, Conen David, Müller Christian, Osswald Stefan, Gilgen Nicole, Vuilliomenet André, Pedrazzini Giovanni, Pfisterer Matthias, Vogt Deborah R, Galatius Søren, Abildgaard Ulrik, Naber Christoph, Alber Hannes, Eberli Franz, Kurz David J, Kaiser Christoph
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial
Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliomenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention 2018; 14:692-699.
20.08.2018A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial
20.08.2018EuroIntervention 2018; 14:692-699
Iglesias Juan F, Windecker Stephan, Jüni Peter, Eeckhout Eric, Valgimigli Marco, Heg Dik, Tapponnier Maxime, Kaiser Christoph, Weilenmann Daniel, Vuilliomenet André, Kurz David J, Roffi Marco, Zaugg Serge, Muller Olivier, Pilgrim Thomas
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
Pilgrim T, Jüni P, Wenaweser P, Blöchlinger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. EuroIntervention 2015; 11
23.12.2015Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
23.12.2015EuroIntervention 2015; 11
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Blöchlinger Stefan, Nietlispach Fabian, Rigamonti Fabio, Taniwaki Masanori, Khattab Ahmed A, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Muller Olivier, Vuilliomenet André, Tüller David, Roffi Marco, Heg Dik, Piccolo Raffaele, Windecker Stephan
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial
Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. Circ Cardiovasc Interv 2015; 8
01.06.2015Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial
01.06.2015Circ Cardiovasc Interv 2015; 8
Franzone Anna, Jüni Peter, Wenaweser Peter, Stortecky Stefan, Räber Lorenz, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Muller Olivier, Vuilliomenet André, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas, Windecker Stephan
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014; 384:2111-22.
01.09.2014Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
01.09.2014Lancet 2014; 384:2111-22
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Eberli Franz R, Noble Stéphane, Moschovitis Aris, Fahrni Therese, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Heg Dik, Windecker Stephan
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial
Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. Am Heart J 2014; 168:256-61.
06.06.2014Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial
06.06.2014Am Heart J 2014; 168:256-61
Pilgrim Thomas, Jüni Peter, Heg Dik, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Windecker Stephan
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
Maeder M, Brunner-La Rocca H, Pfisterer M, Peter M, Vuilliomenet A, Erne P, Gutmann M, Abbühl H, Rickli H, Rickenbacher P, TIME-CHF Investigators. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail 2013; 15:1148-56.
08.05.2013N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
08.05.2013Eur J Heart Fail 2013; 15:1148-56
Maeder Micha, Brunner-La Rocca Hans-Peter, Pfisterer Matthias, Peter Martin, Vuilliomenet André, Erne Paul, Gutmann Marc, Abbühl Heidi, Rickli Hans, Rickenbacher Peter, TIME-CHF Investigators
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design
Jeger R, Gilgen N, Vuilliomenet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J 2012; 163:136-41.e1.
01.02.2012Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design
01.02.2012Am Heart J 2012; 163:136-41.e1
Jeger Raban, Gilgen Nicole, Vuilliomenet André, Jensen Jan Skov, Rickli Hans, Pedrazzini Giovanni, Naber Christoph, Galatius Søren, Eberli Franz, Alber Hannes, Pfisterer Matthias, Kaiser Christoph